Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A diluent and pharmaceutical technology, applied in the direction of anti-inflammatory agent, antiviral agent, non-central analgesic agent, etc., can solve the problem of anatomical separation of fetal antigen immaturity and so on
Inactive Publication Date: 2010-12-29
NEWLINK GENETICS
View PDF12 Cites 42 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Maternal-fetal anatomical separation and fetal antigenic immaturity do not fully account for fetal allograft survival
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0834] Method A: Synthesis of allosteric dithiocarbamates with S-alkyl groups (Scheme 1)
[0835] Diagram 1.
[0836]
[0837] at 0 °C in anhydrous CH 2 Cl 2 A solution of tryptamine 1 (1.1 equiv) was treated with triethylamine (1.1 equiv) followed by carbon disulfide (1.1 equiv) in (10 mL) and stirred for 30 minutes. After this time, alkyl bromide 2 (1.2 equiv unless otherwise stated) was added and the reaction was allowed to warm to room temperature and stirred overnight. The reaction mixture was then poured into 1M H 2 SO 4 and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with brine, in anhydrous Na 2 SO 4 Dry, then filter and concentrate. Purification by flash chromatography (silica, ethyl acetate / hexanes) afforded the desired product. pass 1H nuclear magnetic resonance spectroscopy observation, dithiocarbamate products generally exist in the form of about 7:3 tautomeric mixture, and listed spectral data.
[0841] The reaction of 1 with (2-bromoethyl)benzene (1.2 eq.) was carried out as described in Method A. Purification by flash chromatography (silica, gradient 12% ethyl acetate / hexanes to 100% hexanes) afforded the product 00001 (0.148 g, 35%) as a yellow oil: 1 H nuclear magnetic resonance spectroscopy (500MHz, CDCl 3 ), 8.04(br s, 1H), 7.62(d, J=7.5Hz, 1H), 7.38(d, J=8.0Hz, 1H), 7.32-7.25(m, 2H), 7.25-7.20(m, 4H ), 7.16-7.13(m, 1H), 7.07-7.05(m, 1H), 6.92(br s, 1H), 4.11-4.06(m, 2H), 3.48-3.45(m, 2H), 3.13(t, J = 6.5Hz, 2H), 2.97-2.94(m, 2H) and signal due to minor tautomers (about 31%): 3.78-3.74(m), 3.59-3.55(m), 3.10-3.08 (m), 3.05-3.01(m); ESI MSm / z 341[M+H] + , HPLC (method 1)>99% (AUC), t R = 13.9 minutes.
[0845] Reaction of 1 with 4-fluorophenethyl bromide (0.6 equiv) was carried out as described in Method A. Purification by flash chromatography (silica, gradient 12% ethyl acetate / hexanes to 100% ethyl acetate) afforded the product 00003 (0.084 g, 31%) as a yellow oil: 1 H nuclear magnetic resonance spectroscopy (500MHz, CDCl 3 ), 8.04(br s, 1H), 7.63(d, J=8.0Hz, 1H), 7.39(d, J=8.0Hz, 1H), 7.24-7.13(m, 4H,), 7.08-7.04(m, 1H), 7.00-6.94(m, 2H), 6.92(br s, 1H), 4.11-4.07(m, 2H), 3.46-3.43(m, 2H), 3.14(t, J=7.0Hz, 2H), 2.94-2.91(m, 2H) and signal due to slight tautomers (about 31%): 3.79-3.75(m), 3.55-3.52(m), 3.11-3.09(m), 3.01-2.98( m); ESI MSm / z 359 [M+H] + , HPLC (method 1) 95.3% (AUC), t R = 13.7 minutes.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.
Description
[0001] Cross References to Related Applications [0002] This application is asserted under 35 USC § 119(e) of U.S. Provisional Application No. 60 / 991,518, filed November 30, 2007, and U.S. Provisional Application No. 61 / 050,646, filed May 6, 2008 Japanese rights and interests; two applications are fully incorporated in the present invention by reference. field of invention [0003] This aspect relates to compounds and methods for inhibiting indoleamine 2,3-dioxygenase; the invention further relates to methods of treating diseases or disorders mediated by indoleamine 2,3-dioxygenase. Background technique [0004] Tryptophan (Trp) is an essential amino acid required for the biosynthesis of proteins, niacin, and the neurotransmitter serotonin (serotonin). The enzyme indoleamine 2,3-dioxygenase (also known as INDO or IDO) catalyzes the first and rate-limiting step in the degradation of L-tryptophan to N-formyl-kynuric acid step. In human cells, IFN-γ-stimulated induction lea...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more